OTCMKTS:GNMSF Genmab A/S Q4 2025 Earnings Report $343.00 0.00 (0.00%) As of 09/18/2026 ProfileEarnings History Genmab A/S EPS ResultsActual EPS$0.55Consensus EPS $3.10Beat/MissMissed by -$2.55One Year Ago EPSN/AGenmab A/S Revenue ResultsActual Revenue$1.06 billionExpected Revenue$1.05 billionBeat/MissBeat by +$5.60 millionYoY Revenue GrowthN/AGenmab A/S Announcement DetailsQuarterQ4 2025Date2/17/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsGenmab A/S' next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Genmab A/S Earnings HeadlinesGenmab A/S (OTCMKTS:GNMSF) Shares Gap Up - Still a Buy?September 18 at 5:02 AM | americanbankingnews.comGenmab Updates Articles of Association, Preserves Broad Capital-Raising PowersSeptember 9, 2026 | tipranks.comNo Wallstreet. No Advisor. No Problem.Savings accounts pay just 0.58 percent interest. Andy Howard, co-founder of Meridian Capital, says liquidity pools offer a different route to passive income. No brokerage account, no advisor, no minimum net worth required. Howard has guided over 23,000 people across 128 countries and says you can start with as little as $50.September 20 at 1:00 AM | Awesomely (Ad)Genmab Calls October Extraordinary General Meeting to Address Board Remuneration and Shareholder OutreachSeptember 8, 2026 | tipranks.comCould Genmab (GMAB) Stock Win as Royalty Growth Fuels a New Earnings Cycle?August 26, 2026 | insidermonkey.comGenmab Updates Articles of Association, Expands Capital-Raising FlexibilityAugust 12, 2026 | tipranks.comSee More Genmab A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Genmab A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genmab A/S and other key companies, straight to your email. Email Address About Genmab A/SGenmab A/S (OTCMKTS:GNMSF) is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing antibody-based medicines for cancer and other serious diseases. Founded in 1999, the company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system and target disease-related cells. Genmab’s products include Darzalex (daratumumab), developed with Janssen Biotech for certain blood cancers; Epkinly (epcoritamab), developed with AbbVie for certain types of B-cell lymphoma; and Tivdak (tisotumab vedotin), developed with Seagen, now part of Pfizer, for recurrent or metastatic cervical cancer. Genmab also discovered the antibody underlying Kesimpta (ofatumumab), a Novartis treatment for multiple sclerosis. The company continues to advance a pipeline of proprietary and partnered antibody therapeutics. Genmab serves international markets through its own research and development operations and collaborations with global pharmaceutical companies. Its activities extend across North America, Europe and Asia, with corporate and research operations in Denmark and the United States as well as additional international locations. Jan van de Winkel, a co-founder of Genmab, has served as the company’s chief executive officer since 2010.View Genmab A/S ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingThese 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity PushGold Has Gone Sideways, But These 3 Stocks Haven’tLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in Focus Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
